摘要
国家提出通过创新驱动发展战略引领制药产业转型发展,重大新药创制专项是实现药品自主创新的攻坚项目。本文通过文献分析对重大新药创制科研专项中机构合作,以及机构合作网络的核心机构、网络特性等进行了综述。新药专项的实施促进了我国新药源头创新能力的提升。企业应重视源头创新,加深产学研医合作。相关科技管理工作在制定新药创新政策时,应注意合理分配科研经费,提高科研效益。
China has implemented the innovation-driven development strategy to drive the transformation and development of the pharmaceutical industry.The Special Project for Significant New Drug Research and Development in the Major National Science and Technology Projects of China is a tackling key project to achieve independent innovation of drugs.This paper analyzes the scientific cooperation networks for the Special Project on New Drugs,in terms of the insti tutional cooperation,core institutions and network characteristics.The implementation of the Special Project on New Drugs has improved the capacity to make original drug innovations in China.Enterprises should pay more attention to the original innovations and deepen the cooperation with related industries,universities and research institutions.In addi tion,when the relevant government departments formulate special policies for the new drug research and development,more attention should be paid to the allocation of research funds to improve related research efficiencies.
作者
徐佳琳
翁开源
XU Jia-lin;WENG Kai-yuan(Guangdong Pharmaceutical University,Guangzhou 510006,China)
出处
《国际药学研究杂志》
CAS
北大核心
2019年第7期485-491,共7页
Journal of International Pharmaceutical Research